On Monday, March 22, NOAA's Oceans and Human Health Initiative will host two briefings to key House and Senate staffers on NOAA's efforts to improve understanding and management of the ocean, coasts, and Great Lakes to enhance benefits to human health and reduce public health risks. Panelists from NOAA and academia will highlight partnerships and success stories from across the U.S. on beach, seafood, and drinking water safety; sentinel species and habitats health and insights for human health; and drug discoveries from the sea...
Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug fondaparinux with Emisphere's EligenŽ Technology. Emisphere's broad-based drug delivery platform, known as the EligenŽ Technology, uses proprietary, synthetic carriers to enhance the oral bioavailability of a drug without altering its chemical form or biological activity. Fondaparinux, an anti-coagulant used for the prevention of deep vein thrombosis, is marketed in injectable form as ArixtraŽ by GlaxoSmithKline...
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that primary and secondary endpoints were not met in Novelos' pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy. Adding NOV-002 to paclitaxel and carboplatin chemotherapy was not statistically or meaningfully different in terms of efficacy-related endpoints or recovery from chemotherapy toxicity versus chemotherapy alone...